Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUCO-TAVR: Glucocorticoids in TAVR
NCT06076824Phase 4Unknown
- Sponsor
- Hospital General Universitario de Alicante
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone injection and prednisone in Atrioventricular Block (AVB) and bundle branch block (BBB) (2 arms), sponsored by Hospital General Universitario de Alicante. Primary endpoint: Composite of permanent pacemaker implantation and the occurrence of new conduction abnormalities at 1 year. Status: unknown.
02
Drugs
methylprednisolone injectionprednisone
03
Conditions
Atrioventricular Block (AVB)bundle branch block (BBB)
Beyond the preview
Go deeper on NCT06076824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076824.